PI3K/Akt Pathway: A Potential Therapeutic Target for Chronic Pain

Author(s): Shu-Ping Chen, Ya-Qun Zhou, Dai-Qiang Liu, Wen Zhang, Anne Manyande, Xue-Hai Guan, Yu-ke Tian, Da-Wei Ye*, Deeq Mohamed Omar

Journal Name: Current Pharmaceutical Design

Volume 23 , Issue 12 , 2017

Become EABM
Become Reviewer
Call for Editor


Chronic pain is among the most disabling and costly disorders, with prevalence ranging from 10% to 55%. However, current therapeutic strategies for chronic pain are unsatisfactory due to our poor understanding of its mechanisms. Thus, novel therapeutic targets need to be found in order to improve these patients’ quality of life. PI3K and its downstream Akt are widely expressed in the spinal cord, particularly in the laminae I-IV of the dorsal horn, where nociceptive C and Aδ fibers of primary afferents principally terminate. Recent studies have demonstrated their critical roles in the development and maintenance of chronic pain. In this review, we summarized the roles and mechanisms of PI3K/Akt pathway in the progression of chronic pain through sciatic nerve injury, diabetic neuropathy, spinal cord injury, bone cancer, opioid tolerance, or opioid-induced hyperalgesia.

Keywords: PI3K, Akt, chronic pain, bone cancer pain, neuropathic pain, inflammatory pain, opioid tolerance.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Published on: 12 May, 2017
Page: [1860 - 1868]
Pages: 9
DOI: 10.2174/1381612823666170210150147
Price: $65

Article Metrics

PDF: 62
HTML: 15